Interchange Capital Partners LLC Cuts Holdings in Medicus Pharma Ltd $MDCX

Interchange Capital Partners LLC trimmed its position in Medicus Pharma Ltd (NASDAQ:MDCX) by 4.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,586,871 shares of the company’s stock after selling 75,000 shares during the period. Medicus Pharma makes up approximately 1.1% of Interchange Capital Partners LLC’s holdings, making the stock its 16th biggest holding. Interchange Capital Partners LLC owned 11.69% of Medicus Pharma worth $4,745,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. SeaCrest Wealth Management LLC acquired a new stake in Medicus Pharma in the second quarter valued at approximately $139,000. Private Advisor Group LLC acquired a new stake in Medicus Pharma in the first quarter valued at approximately $211,000. Guyasuta Investment Advisors Inc. acquired a new stake in Medicus Pharma in the second quarter valued at approximately $230,000. Finally, Armistice Capital LLC acquired a new stake in Medicus Pharma in the first quarter valued at approximately $4,710,000.

Medicus Pharma Trading Up 11.1%

NASDAQ:MDCX opened at $2.70 on Friday. Medicus Pharma Ltd has a 12 month low of $1.79 and a 12 month high of $8.94. The firm has a fifty day simple moving average of $2.32 and a 200-day simple moving average of $3.14. The company has a market capitalization of $48.11 million and a P/E ratio of -2.01.

Medicus Pharma (NASDAQ:MDCX) last issued its earnings results on Monday, August 11th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.04). Equities analysts forecast that Medicus Pharma Ltd will post -1.14 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Medicus Pharma in a research note on Saturday. Zacks Research upgraded shares of Medicus Pharma to a “hold” rating in a research note on Monday, September 15th. Finally, D. Boral Capital reiterated a “buy” rating and set a $27.00 price objective on shares of Medicus Pharma in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $23.50.

Medicus Pharma Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.